We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Antioxidant Shown to Prevent Diabetes in Mice

By Biotechdaily staff writers
Posted on 21 May 2002
A study has shown that a synthetic antioxidant can delay and prevent the onset of autoimmune diabetes in mice. More...
The study, reported in the February 2002 issue of Diabetes, was conducted by researchers at the National Jewish Medical and Research Center (Denver, CO, USA) and the University of Colorado Health Sciences Center (Denver, CO, USA).

The antioxidant not only protected insulin-producing beta cells from destructive oxygen radicals but also prevented the immune system from recognizing beta cells, its target in diabetes. The researchers used a synthetic catalytic antioxidant called AEOL 10113, which mimics the naturally occurring antioxidant superoxide dismutase but works against a wider range of oxygen radicals and lasts longer in the body.

The antioxidant was injected into 10 mice one day before transplanting T cells to cause diabetes and four more times afterward, with the last injection on day nine. The five control mice all became diabetic by day 13, while none of the treated mice showed any signs of diabetes until day 21. Half of the treated mice remained diabetes free after four weeks. Subsequent experiments showed that the antioxidant can prevent the immune system from recognizing specific antigens, suggesting that the antioxidant might be used with specific antigens to treat other autoimmune diseases as well as diabetes.

"These data show that antioxidants protect against diabetes on two fronts,” said James Crapo, M.D., co-author of the study and chairman of the department of medicine at National Jewish. "They not only mop up destructive oxygen radicals, but also alter the immune response.” The AEOL 10113 antioxidant was developed by Dr. Crapo and colleagues.



Related Links:
National Jewish Medical and Research Center
Univ. of Colorado

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.